Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.
Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.
At AACR 2018, Dr. Aung Naing of MD Anderson presented ECHO-203, the first data on epacadostat in combination with an anti–PD-L1 inhibitor.
A biomarker known as RAD51 was found to be correlated with resistance to PARP inhibitor treatment in a study of breast cancer that harbors BRCA mutations.
At AACR 2018, Dr. Alexander Eggermont presented results of KEYNOTE-045/EORTC 1325-MG, in which melanoma patients with recurrence on placebo can receive pembrolizumab.
Laboratory studies suggest that mechanisms of resistance to tyrosine kinase inhibitor therapy differ between the specific subtypes of HER2-positive breast cancer.
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The combination of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib yielded improved progression-free survival over vemurafenib in patients with advanced BRAF V600–mutant melanoma.
The combination of nivolumab with an interleukin-15 agonist was well tolerated with no dose-limiting toxicities in patients with metastatic non–small-cell lung cancer.
Pembrolizumab offered stable or improved measures of global health status and quality of life compared with chemotherapy in patients with previously treated advanced urothelial cancer.